Ignite Creation Date:
2025-12-25 @ 2:30 AM
Ignite Modification Date:
2026-05-29 @ 6:25 AM
Study NCT ID:
NCT00412334
Status:
COMPLETED
Last Update Posted:
2016-04-05
First Post:
2006-12-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.
Sponsor:
Hoffmann-La Roche
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ML20399
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None